PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

Pharm Exec's Brands of the Year 2017

Scott Gottlieb's Multiple FDA Challenges

Leadership: Failure is an Option

Top Story
UK Political Parties Set Out Pharma Plans Ahead of Election
With the UK's General Election set for next week, Leela Barham looks what the competing parties are promising for pharma and healthcare
/Read more/
Advertisement
Text Ad title -1
Text Ad description
Read More
ADVERTISEMENT
Europe
A Long Summer of Drug Pricing Tension Looms
In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector
/Read more/
Advertisement
Text Ad title -2
Text Ad description
Read More
Call for Nominations
Pharm Exec's Emerging Pharma Leaders 2017 — Nominate Here
Read here for details of how to nominate a colleague — or yourself — for Pharm Exec's annual Emerging Pharma Leaders feature
/Read more/
Advertisement
Text Ad title -3
Text Ad description
Read More
Regulatory
FDA Looks to Advance Regenerative Medicine
The Center for Biologics Evaluation and Research (CBER) is gearing up to facilitate the development and approval of regenerative medicine advanced therapies, as defined by the 21st Century Cures Act, writes Jill Wechsler
/Read more/
Advertisement
Text Ad title -7
Text Ad description
Read More
Calendar
/ June 6–7: Pharmaceutical Compliance Congress Canada /
Toronto, CA
/ June 22–23: Patient Engagement Solutions Summit /
Philadelphia, PA
/ June 27–28: Publication and Clinical Trial Transparency /
Barcelona, Spain
/ August 8–9: Bio/Pharma Strategic Portfolio Management Summit /
Cambridge, MA
/ September 14–15: Risk Based Global Monitoring 2017 /
Barcelona, Spain
/ October 24–25: 12th Annual Value-Based Oncology Management /
Scottsdale, AZ
/ February 27–28, 2018: Speaker Programs 2018 /
Philadelphia, PA
Advertisement
Text Ad title -4
Text Ad description
Read More
Advertisement
Text Ad title -6
Text Ad description
Read More
Competitive Advantage
Reinventing the Role of Medical Affairs
As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator, write Loic Plantevin, Christoph Schlegel and Maria Gordian
/Read more/
Advertisement
Text Ad title -8
Text Ad description
Read More
Outlook
Pharma & Biotech Forecast: Outlook Sunny, But Uncertain
Peter Young presents a summary of the strategic issues facing the biopharma industry, reviews recent M&A and financing activity, and looks at the implications for senior management
/Read more/
Advertisement
Text Ad title -9
Text Ad description
Read More
Industry update
//Constellation Pharmaceuticals (Cambridge, MA) appointed Jigar Raythatha as President and CEO. //Concert Pharmaceuticals (Lexington, MA) announced that Ryan Daws, Chief Financial Officer, will be leaving the company in early June 2017 to return to investment banking. //Genecentric Therapeutics (Durham, NC) appointed Walter M. Capone as Chief Business Officer and added Ellen Lubman to its Board of Directors. //Rosa & Co. (San Carlos, CA) appointed Matt Marano as Senior Vice President of Business Development//
Advertisement
Advertisement
Text Ad title -10
Text Ad description
Read More
 
advertise with us / print subscribe / digital subscribe / visit pharmexec.com